MANAGEMENT OF IMMUNOTHERAPY RELATED GI AND HEPATIC ADVERSE EVENTS
|
|
- Justin Hampton
- 5 years ago
- Views:
Transcription
1 MANAGEMENT OF IMMUNOTHERAPY RELATED GI AND HEPATIC ADVERSE EVENTS Wai K. Leung Li Shu Fan Medical Foundation Professor in Gastroenterology Associate Dean (Human Capital), LKS Faculty of Medicine, University of Hong Kong Deputy Director, Integrated Endoscopy Centre, Queen Mary Hospital, Hong Kong
2 IMMUNOTHERAPY RELATED GI AND LIVER ADVERSE EVENTS 11 RCTs involving 5307 patients Risk ratios for combination therapy were: all-grade diarrhea: 1.95 (95% CI 1.54, 2.46; P < ) all-grade colitis: 4.45 (95% CI 3.04, 6.51; P < ). all-grade increased AST: 3.87 (95% CI 2.74, 5.47; P < ) all-grade increased ALT: 4.29 (95% CI 3.05, 6.04; P < ) Zhang B et al. Int Immunopharmacol 2018
3 DIARRHEA AND COLITIS Usually occur within 6wk of starting therapy Median time to onset of diarrhea 5-8 wk after ipilimimab, 3-6 mths after anti-pd-1 Higher for CTLA-4 than PD-1 receptor inhibitors. Incidence of grade ¾ colitis is 7% and 1.8%, respectively. Perforation has been reported, particularly after CTLA-4 inhibitors
4 CTLA-4 VS ANTI-PD-1 Khoja L et al. Ann Oncol 2017
5 COLITIS IN PATIENTS TREATED WITH ANTI- PD1 Baxi S et al. BMJ 2018
6 NO INCREASE IN DIARRHEA Baxi S et al. BMJ 2018
7 DIARRHEA GRADING: COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (CTCAE) V.4 Grade 1: increase of <4 stools per day over baseline. Grade 2: increase of 4 6 stools per day over baseline. Grade 3: increase of 7 or more stools per day over baseline, incontinence, hospitalisation indicated, limiting self-care activities of daily living. Grade 4: life-threatening consequences, urgent intervention indicated. Grade 5: death
8 COLITIS GRADING: CTCAE V.4 Grade 1: asymptomatic, clinical or diagnostic observations only, intervention not indicated. Grade 2: abdominal pain, mucus or blood in stool. Grade 3: severe abdominal pain, change in bowel habits, medical intervention indicated, peritoneal signs. Grade 4: life-threatening consequences, urgent intervention indicated. Grade 5: death
9 MANAGEMENT Exclude infections (CMV, Cl. difficile, etc) Grade 1 Symptomatic Rx Grade 2 Withhold immunotherapy, anti-diarrheal agents Consider steroid in persistent symptoms. Grade 3-4 Stop immunotherapy Start systemic steroid Infliximab (anti-tnf) in severe cases
10 TREATMENT FOR COLITIS Cortisocteroid Budesonide (9mg) can also be used in mild case Severe case or not responding to budesonide, oral prednisolone at 1-2mg/kg/day or IV methylprednisolone up to 2mg/kg twice a day Infliximab 5mg/kg every 2 wk
11 ENDOSCOPY FOR DIARRHEA Only recommended for persistent grade 2 or above diarrhea since it seldom affect management CT showed mild diffuse bowel thickening Can range from normal endoscopic appearance to severe inflammatory changes with exudates, granularity, erythema, loss of vascularity and erosions/ulcers Biopsy recommended in all cases Usually pancolitis, and minority of left side colitis
12 ENDOSCOPIC APPEARANCES OF COLITIS 42 (68%) had a pancolitis ( 3 affected segments). Ulcers were seen in 32% of endoscopies. There was no significant correlation between the grade of diarrhoea at presentation and endoscopic severity scores Geukes Foppen MH et al. ESMO Open 2018
13 HISTOLOGICAL FEATURES Autoimmune-like colopathy in CTLA-4 inhibitors Dense, predominantly lymphocytic infiltrate in the lamina propria along with frequent plasma cells and eosinophils Neutrophilic inflammation is commonly seen, including neutrophilic cryptitis and crypt microabscesses, as well as increased crypt epithelial apoptosis Variable increase in intraepithelial lymphocytes (IELs) In most studies, features of chronicity are typically absent. Granulomas are absent. Anti-PD-1-induced colitis increased apoptosis and crypt atrophy/dropout active mucosal injury, including neutrophilic crypt microabscesses and cryptitis, Granulomas associated with ruptured crypts are seen in 18% of biopsies. Chronicity can be present
14 HISTOLOGICAL FEATURES OF COLITIS Lymphocytic colitis increased apoptosis Karamchandani DM, J Clin Pathol 2018
15 Friedman CF, et al. JAMA Oncol 2016
16 CYCLOSPORINE FOR REFRACTORY CASE Cyclosporine 50mg oral after failure of steroid and infliximab Iyoda T, et al. Am J Case Rep 2018
17 VEDOLIZUMAB 7 patients with metastatic melanoma or lung cancer, treated with vedolizumab for ipilimumab- or nivolumab-induced enterocolitis all patients but one experienced steroid-free enterocolitis remission, with normalized fecal calprotectin Median 56 days after vedolizumab Berggvist V et al. Cancer Immunol Immunother 2017
18 OUTCOMES OF DIARRHEA/COLITIS Development of diarrhea and/or colitis during use of 1 checkpoint inhibitor does not necessarily prohibit the use of another Mortality associated with colitis is rare No effective prevention
19 HEPATIC ADVERSE EVENTS Less frequent than GI adverse events 3-10% of patients More frequently with CTLA-4 blocking antibodies and combination of both Asymptomatic increase in AST and ALT Most often 8-12 wk after starting therapy but may occur at any time Imaging usually normal. Severe case show conspicuous periportal echogenicity, edema of GB, and even hepatomegaly
20 HEPATITIS AND ANTI-PD1 Baxi S et al. BMJ 2018
21 HEPATITIS GRADING: CTCAE V.4 Grade 1: AST or ALT upper limit of normal (ULN) and/or T-BIL1 1.5 ULN. Grade 2: AST or ALT ULN and/or T-BIL ULN. Grade 3: AST or ALT >5 ULN and/or T-BIL >3 ULN. Grade 4: AST or ALT >8 ULN. Grade 5: death.
22 HISTOLOGICAL FEATURES Anti-CTLA-4 Active panlobular hepatitis with a mixed inflammatory infiltrate consisting predominantly of lymphocytes Centrilobular (zone 3) hepatitis Anti-PD-1 Few reports Predominantly lobular hepatitis with milder portal inflammation
23 CHECKPOINT INHIBITOR-INDUCED HEPATIC INJURY active panlobular hepatitis Karamchandani DM, J Clin Pathol 2018
24 DIFFERENTIAL DIAGNOSIS Autoimmune hepatitis ANA, anti-smooth muscle antibody IgG levels Viral hepatitis HBsAg, anti-hbc, anti-hbs Anti-HAV, anti-hev IgM anti-hcv Drug induced liver injury (DILI) Liver biopsy is usually necessary for assessment of disease severity
25 TREATMENT Discontinuation of immunotherapy Corticosteroid Prednisone 1-2 mg/kg/d Methylprednisolone mg/kg/d Combination with MMF ( mg every 12h) or Tarcolimus Anti-thymocyte globulin (ATG) in highly refractory case with rapid clinical decompensation May take >1 month to resolve
26 De Martin E, J Hepatol 2018
27 TREATMENT De Martin E, J Hepatol 2018
28 Friedman CF, et al. JAMA Oncol 2016
29 CONCLUSION CTLA-4 inhibitors tend to have more GI and liver AEs than anti-pd-1 Acute hepatitis resulting from immunotherapy is not common (3.5%) and, in most cases, not severe. Colonoscopy/sigmoidoscopy has limited role on the diagnosis of GI side effects. Liver biopsy would be helpful for the diagnosis and evaluation of the severity of liver injury. The mainstay of irae treatment consists of immunosuppression with corticosteroids or other immunosuppressant agents such as infliximab; most iraes will resolve with appropriate management.
MANAGEMENT OF IMMUNE-RELATED GI AND LIVER TOXICITY
MANAGEMENT OF IMMUNE-RELATED GI AND LIVER TOXICITY Alberto Fusi Charité Comprehensive Cancer Centre - Berlin St. George s University - London TAO Meeting - Cancer Toxicity Management Paris - 8th-9th December
More informationOPTIMAL MANAGEMENT OF IMMUNE- RELATED ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT INHIBITORS
OPTIMAL MANAGEMENT OF IMMUNE- RELATED ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT INHIBITORS Alberto Fusi Charité Comprehensive Cancer Centre Berlin, Germany 1 Immune check point blockade with CTLA-4, anti-pd-1
More informationManaging Checkpoint Inhibitor Toxicities. Megan L. Menon, Pharm.D., BCOP Roswell Park Cancer Institute
Managing Checkpoint Inhibitor Toxicities Megan L. Menon, Pharm.D., BCOP Roswell Park Cancer Institute Approved Indications Ipilimumab Nivolumab Pembrolizumab* Atezolizumab Avelumab Durvalumab Ipi + Nivol
More informationCANCER IMMUNOTHERAPY. Pocket Guide
CANCER IMMUNOTHERAPY Pocket Guide Unique Clinical Features Tumor Response Kinetics Response patterns associated with immune checkpoint blockade may differ from those associated with conventional therapies,
More informationMANAGEMENT OF IMMUNE-RELATED SIDE EFFECTS OF IMMUNE CHECKPOINT INHIBITORS
MANAGEMENT OF IMMUNE-RELATED SIDE EFFECTS OF IMMUNE CHECKPOINT INHIBITORS John B.A.G. Haanen MD PhD CONTENT OF THIS PRESENTATION General aspects of immune related adverse events related to immune checkpoint
More informationOncologist-induced Disease of the GI tract: New Developments
Oncologist-induced Disease of the GI tract: New Developments Jeffrey D Goldsmith, MD Children s Hospital Boston, Beth Israel Deaconess Medical Center, Harvard Medical School Boston, MA Everyone s on drugs
More informationBCCA Protocol Summary for the Treatment of Unresectable or Metastatic Melanoma Using Nivolumab
BCCA Protocol Summary for the Treatment of Unresectable or Metastatic Melanoma Using Nivolumab Protocol Code Tumour Group Contact Physician USMAVNIV Skin and Melanoma Dr. Kerry Savage ELIGIBILITY: Unresectable
More informationHistological and immunological characteristics of colitis associated with anti-ctla 4 antibody therapy
Histological and immunological characteristics of colitis associated with anti-ctla 4 antibody therapy M. Perdiki 2, G. Bamias 1, D. Pouloudi 2, H. Gogas 3, I. Delladetsima 2 1 Academic Dpt. of Gastroenterology,
More informationAutoimmune Hepatitis. Dr. Stefania Casu Hepatology, UVCM, Inselspital Bern. November 14th, 2018
Autoimmune Hepatitis Dr. Stefania Casu Hepatology, UVCM, Inselspital Bern November 14th, 2018 AIH - Definition Manns MP J Hepatol 2015, vol 62, P 100-111 AIH - Definition Autoimmune hepatitis (AIH) is
More informationIpilimumab in Melanoma
Ipilimumab in Melanoma Indication: Advanced (unresectable or metastatic) melanoma in adults who have received prior therapy LCNDG criteria to be met: Histologically confirmed unresectable stage III or
More informationComplications of Immunotherapy
Complications of Immunotherapy Sarah Norskog, PharmD, BCOP Oncology Pharmacy Specialist University of Colorado Hospital Disclosures I have no relevant financial relationships with commercial interests
More informationBC Cancer Protocol Summary for Treatment of Advanced Non- Small Cell Lung Cancer Using Pembrolizumab
BC Cancer Protocol Summary for Treatment of Advanced Non- Small Cell Lung Cancer Using Pembrolizumab Protocol Code Tumour Group Contact Physician ULUAVPMB Lung Dr. Christopher Lee ELIGIBILITY: Advanced
More informationQ: How should we diagnose and manage
1-MINUTE CONSULT FREEHA KHAN, MD Inflammatory Bowel Disease Fellow, Department of Gastroenterology, Hepatology, & Nutrition, Cleveland Clinic TRACY L. HULL, MD Surgical Head, Section of Inflammatory Bowel
More informationImmunotherapy Treatment Developments in Medical Oncology
Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired
More informationImmune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities
Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities Jeryl Villadolid
More informationCheckpoint inhibitors: Strategies to checkmate T-cell mediated toxicity. Disclosure Statement. Learning Objectives
Checkpoint inhibitors: Strategies to checkmate T-cell mediated toxicity Adam J. DiPippo, PharmD Clinical Pharmacy Specialist Leukemia Texas Society of Health-System Pharmacists 2017 Annual Seminar April
More informationSafety Immune Related Adverse Events (irae) Focus on NSCLC Aaron Hansen, BSc, MBBS, FRACP
Safety Immune Related Adverse Events (irae) Focus on NSCLC Aaron Hansen, BSc, MBBS, FRACP Division of Medical Oncology and Hematology Bras Drug Development Program Princess Margaret Cancer Centre, Toronto,
More informationBCCA Protocol Summary for the Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab
BCCA Protocol Summary for the Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab Protocol Code Tumour Group Contact Physician USMAVIPI Skin and Melanoma Dr. Kerry Savage ELIGIBILITY: Unresectable
More informationWhat is your diagnosis? a. Lymphocytic colitis. b. Collagenous colitis. c. Common variable immunodeficiency (CVID) associated colitis
Case History A 24 year old male presented with fatigue, fever, watery diarrhea, and a cough with sputum production for the past three weeks. His past medical history was significant for recurrent bouts
More informationNursing Perspective on iraes: Patient Education, Monitoring and Management
Nursing Perspective on iraes: Patient Education, Monitoring and Management Rebecca Lewis, CRNP Nurse Practitioner University of Pittsburgh-HCC Shadyside Disclosures No relevant financial relationships
More informationImmune-related adverse events. DrLaviniaSpain MBBS BMedSci FRACP Research Fellow, Skin & Renal Unit Royal Marsden Hospital, London
Immune-related adverse events DrLaviniaSpain MBBS BMedSci FRACP Research Fellow, Skin & Renal Unit Royal Marsden Hospital, London Disclosures I have no relevant disclosures Overview Background principles
More informationAdverse effects of Immunotherapy. Asha Nayak M.D
Adverse effects of Immunotherapy Asha Nayak M.D None Financial Disclosures Objectives Understand intensity of the AEs. Understanding unique side-effects. Develop effective monitoring and management guidelines.
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationManagement of Immune Checkpoint Inhibitor Related Toxicities
Management of Immune Checkpoint Inhibitor Related Toxicities Katie Wolfram, PharmD Clinical Pharmacist, Oncology Memorial Hospital of South Bend A Webinar for HealthTrust Members November 12, 2018 Disclosures
More informationImmunotherapy: Toxicity Management. Dr. Megan Lyle Medical Oncologist Liz Plummer Cancer Care Centre Cairns Hospital
Immunotherapy: Toxicity Management Dr. Megan Lyle Medical Oncologist Liz Plummer Cancer Care Centre Cairns Hospital Disclosures Honoraria and travel support from BMS, MSD, Novartis Advisory board for MSD
More informationBCCA Protocol Summary for Treatment of Metastatic or Advanced Renal Cell Carcinoma Using Nivolumab
BCCA Protocol Summary for Treatment of Metastatic or Advanced Renal Cell Carcinoma Using Nivolumab Protocol Code Tumour Group Contact Physician UGUAVNIV Genitourinary Dr. C. Kollmannsberger ELIGIBILITY:
More informationImmunotherapy for Melanoma. Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center
Immunotherapy for Melanoma Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center Conflicts of Interest Bristol-Myers Squibb: -Research support -Participated
More informationOutcomes of vedolizumab therapy in patients with immune checkpoint inhibitor induced colitis: a multi-center study
Abu-Sbeih et al. Journal for ImmunoTherapy of Cancer (2018) 6:142 https://doi.org/10.1186/s40425-018-0461-4 RESEARCH ARTICLE Open Access Outcomes of vedolizumab therapy in patients with immune checkpoint
More informationMelanoma Immunotherapy. Nursing Perspective on Immune-Related Adverse Events: Patient education, Monitoring & Management
Melanoma Immunotherapy Nursing Perspective on Immune-Related Adverse Events: Patient education, Monitoring & Management Mike Buljan, NP UCSF Medical Center Melanoma Oncology Disclosures None Only FDA-approved
More informationAutoimmune Hepatitis. What Drug and for How Long? Hepatology Day May 30 th, 2015
Autoimmune Hepatitis What Drug and for How Long? Rajaa Chatila, MD Associate Professor of Medicine Director, Internal Medicine Residency Program Lebanese American University Hepatology Day May 30 th, 2015
More informationAutoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP
Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP Autoimmune hepatobiliary diseases The liver is an important target for immunemediated injury. Three disease phenotypes are recognized:
More informationAutoimmune Hepatitis in Clinical Practice
1 Autoimmune Hepatitis in Clinical Practice Atif Zaman, MD MPH Professor of Medicine Senior Associate Dean for Clinical and Faculty Affairs School of Medicine Oregon Health & Science University Disclosure
More informationNovel Therapies in Autoimmune Hepatitis
Novel Therapies in Autoimmune Hepatitis Paul W. Rassam,MD Ass. Clinical Professor of Medicine Div. of Gastroenterology and Hepatology St George Hospital University Medical Center University of Balamand
More informationCase Report Successful Long-Term Use of Infliximab in Refractory Pouchitis in an Adolescent
Gastroenterology Research and Practice Volume 2010, Article ID 860394, 4 pages doi:10.1155/2010/860394 Case Report Successful Long-Term Use of Infliximab in Refractory Pouchitis in an Adolescent Jessica
More informationNEW CONCEPTS IN CROHN S DISEASE GLENDON BURRESS, MD PEDIATRIC GASTROENTEROLOGY ROCKFORD, IL
NEW CONCEPTS IN CROHN S DISEASE GLENDON BURRESS, MD PEDIATRIC GASTROENTEROLOGY ROCKFORD, IL CROHN S DISEASE Chronic disease of uncertain etiology Etiology- genetic, environmental, and infectious Transmural
More informationManagement of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France
Management of autoimmune hepatitis Pierre-Emmanuel RAUTOU Inserm U970, PARCC@HEGP, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France 41 year-old woman, coming to emergency department for fatigue
More informationICLIO Webinar: Immuno-Oncology: From a Community Radiologist Perspective Michael J. DeLeo III, MD
ICLIO Webinar: Immuno-Oncology: From a Community Radiologist Perspective Michael J. DeLeo III, MD Foundation Medical Partners Southern New Hampshire Health System December 1, 2016 accc-iclio.org Overview
More informationPEMBROLIZUMAB (KEYTRUDA ) for the treatment of advanced melanoma or previously treated NSCLC
DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Diluent Rate Day 1 Pembrolizumab 2mg/kg IV Infusion 100mL 0.9% Sodium Chloride* Or 100mL 5% Glucose* *Final concentration must be between 1 to 10mg/mL Over
More information7.3 Suggested Evaluation and Treatment for Immunerelated Adverse Events Gastrointestinal Tract
7.3 Suggested Evaluation and Treatment for Immunerelated Adverse Events Early diagnosis and treatment intervention for high-grade iraes can help prevent the occurrence of complications, such as GI perforation.
More informationOvercoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy. Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016
Overcoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016 Overcoming toxicity A new context for evaluating toxicity
More informationToxicity of Systemic Melanoma Therapies. Alex Guminski Melanoma Institute Australia Royal North Shore Hospital University of Sydney
Toxicity of Systemic Melanoma Therapies Alex Guminski Melanoma Institute Australia Royal North Shore Hospital University of Sydney Disclosures Advisory Board Novartis, BMS, Sanofi, Pfizer Travel support
More informationImmunotherapy. Immunotherapy Triage
Immunotherapy Immunotherapy Triage The most commonly used drug is Ipilimumab for Metastatic Melanoma, but use of immunotherapy is developing in lung cancer and in clinical trials. Drugs include Nivolumab
More informationBCCA Protocol Summary for Treatment of Advanced Non-Small Cell Lung Cancer Using Nivolumab
BCCA Protocol Summary for Treatment of Advanced Non-Small Cell Lung Cancer Using Nivolumab Protocol Code Tumour Group Contact Physician ULUAVNIV Lung Dr. Christopher Lee ELIGIBILITY: Advanced non-small
More informationMimics of Inflammatory Bowel Disease. Dr Catriona McKenzie Royal Prince Alfred Hospital, Camperdown
Mimics of Inflammatory Bowel Disease Dr Catriona McKenzie Royal Prince Alfred Hospital, Camperdown Mimics of IBD: Overview Infections Drugs Autoimmune Other Infections Diagnostic Histopathology, 2015 Case
More informationATEZOLIZUMAB (TECENTRIQ )
DRUG ADMINISTRATION SCHEDULE Day Drug Daily Dose Route Diluent Rate Day 1 Atezolizumab 1200 mg IV Infusion 250mL 0.9% Sodium Chloride Over 60 minutes* *The initial dose of atezolizumab must be administered
More informationCrohn s Disease. Resident Lecture 1/17/19
Crohn s Disease Resident Lecture 1/17/19 Objectives Features/Classification of Crohn s Disease Medical Treatment Surgical Indications Surgical Considerations 2 Case 25 yo F presents to your office with
More informationGESTIONE DELLE TOSSICITÀ IMMUNO-MEDIATE, QUALI LINEE GUIDA?
GESTIONE DELLE TOSSICITÀ IMMUNO-MEDIATE, QUALI LINEE GUIDA? Massimo Di Nicola, MD Unit of Immunotherapy and Anticancer Innovative Therapeutics Medical Oncology Department Widespread use of immune-checkpoint
More informationPositioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT YERVOY 5 mg/ml concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of concentrate contains
More informationCANCER IMMUNOTHERAPY Presented by John A Keech Jr DO MultiCare Regional Cancer Center
CANCER IMMUNOTHERAPY 2018 Presented by John A Keech Jr DO MultiCare Regional Cancer Center Successful anti-cancer immunity is autoimmunity Green, The Scientist, 2014 Immunotherapy strategies Cancer vaccines
More informationATEZOLIZUMAB (TECENTRIQ ) in urothelial carcinoma
DRUG ADMINISTRATION SCHEDULE Day Drug Daily Dose Route Diluent Rate Day 1 Atezolizumab 1200 mg IV Infusion 250mL 0.9% Sodium Chloride Over 60 minutes* *The initial dose of atezolizumab must be administered
More informationNECN CHEMOTHERAPY HANDBOOK PROTOCOL
Nivolumab (Opdivo ) for treatment of advanced melanoma and Renal Cell Cancer (Also advanced/ metastatic NSCLC EMAS patients only -Nov 2016) DRUG ADMINISTRATION SCHEDULE (SINGLE AGENT Day Drug Daily dose
More informationPembrozulimab Induced Collagenous Colitis. Mokshya Sharma 1, MD, Santhosh Ambika 2, MD University of Nevada, Reno SOM
Pembrozulimab Induced Collagenous Colitis Mokshya Sharma 1, MD, Santhosh Ambika 2, MD University of Nevada, Reno SOM Background Immune modulating therapy that targets PD1 pathway such as pembrozulimab
More informationCancer Immunotherapy: Promises and Challenges. Disclosures
Cancer Immunotherapy: Promises and Challenges David B. Page, MD Medical Oncology PMG East Hematology & Oncology Earle A. Chiles Research Institute Portland, Oregon Disclosures Consulting: Celldex, Nektar,
More informationΑπό τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών. Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων
Από τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων Conflict of interest By means of this, the speaker confirms that
More informationCase History B Female patient 1970 Clinical History : crampy abdominal pain and episodes of bloody diarrhea Surgical treatment
Case History B-1325945 Female patient 1970 Clinical History : crampy abdominal pain and episodes of bloody diarrhea Surgical treatment Case History B-1325945 Pathology Submucosa & Muscularis Endometriosis
More informationABDOMINAL PAIN AND DIARRHEA - IT S NOT (ALWAYS) WHAT YOU THINK. Yakov Wainer, MD Gastroenterology and Hepatology Meir Medical Center
ABDOMINAL PAIN AND DIARRHEA - IT S NOT (ALWAYS) WHAT YOU THINK Yakov Wainer, MD Gastroenterology and Hepatology Meir Medical Center 1 ST ADMISSION - 2015 38 y/o female Abdominal pain, diarrhea - intermittent
More informationApproach and management of checkpoint inhibitor-related immune hepatitis
Perspective on Evolving Role of Immune-oncology Therapeutics in GI Malignancies Approach and management of checkpoint inhibitor-related immune hepatitis Aravind Sanjeevaiah 1,2, Thomas Kerr 3, Muhammad
More informationManagement of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France
Management of autoimmune hepatitis Pierre-Emmanuel RAUTOU Inserm U970, PARCC@HEGP, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France Case 1 52 year-old woman, referred for liver blood tests
More informationMucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium
Mucosal Healing in Crohn s Disease Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium Mucosal Lesions in CD: General Features CD can affect the entire GI tract
More information15/05/2015. No conflict of interest for this presentation. The first in-class phosphotidlyinositol3-kinase delta (PI3K delta) inhibitor
Disclosure Idelalisib - A Review No conflict of interest for this presentation Pamela Rudkin PhC Hematology Oncology Pharmacist General Hospital Site Eastern Health Care Corporation Objectives At the completion
More informationManagement of the Hospitalized IBD Patient. Drew DuPont MD
Management of the Hospitalized IBD Patient Drew DuPont MD Ulcerative Colitis: Indications for Admission Severe ulcerative colitis Frequent loose bloody stools ( 6 per day) Severe cramps Systemic toxicity:
More informationManaging immune related toxicity. Karijn Suijkerbuijk May 27 th 2017
Managing immune related toxicity Karijn Suijkerbuijk May 27 th 2017 Disclosures Advisory role: BMS, Merck Travel support: Amgen, Novartis, Roche Whybother? Patients are dying from toxicity Eggermont ipilimumab
More informationCommon Questions in Crohn s Disease Therapy. Case
Common Questions in Crohn s Disease Therapy Jean-Paul Achkar, MD, FACG Kenneth Rainin Chair for IBD Research Cleveland Clinic Case 23 yo male with 1 year history of diarrhea, abdominal pain and 15 pound
More informationNivolumab Ipilimumab Combination Therapy
INDICATIONS FOR USE: Nivolumab Ipilimumab Combination INDICATION ICD10 Regimen Code *Reimbursement Status Nivolumab in combination with ipilimumab is indicated for the treatment of advanced (unresectable
More informationIMMUNOTHERAPY OVERVIEW. Gloria Roldan Urgoiti MD, MSc, FRCPC Tom Baker Cancer Centre April 22, 2017
IMMUNOTHERAPY OVERVIEW Gloria Roldan Urgoiti MD, MSc, FRCPC Tom Baker Cancer Centre April 22, 2017 Faculty/Presenter Disclosure Speaker: Dr. Gloria Roldan Urgoiti Relationships with commercial interests:
More information하부위장관비종양성질환의 감별진단 주미인제의대일산백병원
하부위장관비종양성질환의 감별진단 주미인제의대일산백병원 Solutions for diagnostic problems in Colitis : Please ask yourself five questions Normal or Inflamed? Acute or Chronic? IBD or Other chronic colitis? Ulcerative colitis or
More informationIpilimumab Monotherapy
INDICATIONS FOR USE: Ipilimumab INDICATION ICD10 Regimen Code *Reimbursement Indicator Treatment of advanced (unresectable or metastatic) melanoma in adults C43 00105a ODMS *If a reimbursement indicator
More informationManagement of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology 28 (Supplement 4): iv119 iv142, 2017 doi:10.1093/annonc/mdx225 CLINICAL PRACTICE GUIDELINES Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis,
More informationManagement of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
CLINICAL PRACTICE GUIDELINES Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up J. B. A. G. Haanen 1, F. Carbonnel 2, C. Robert 3, K.
More informationImmune-Related Adverse Reaction (irar) Management Guide
REGIMEN Immune-Related Adverse Reaction (irar) Management Guide OPDIVO as monotherapy is indicated for the treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) with progression
More informationUlcerative Colitis Therapy. Faculty Disclosure. Acknowledgements 28/11/2013. Amy Morse November 30/13
Ulcerative Colitis Therapy Amy Morse November 30/13 GI for GP s Jasper AB Faculty Disclosure Faculty: Amy Morse Relationships with commercial interests: Grants/Research Support: Therapeutic Fellowship
More informationImmune Checkpoint Therapy Toxicities: Lessons learned and new strategies to improve outcomes
Immune Checkpoint Therapy Toxicities: Lessons learned and new strategies to improve outcomes Geoffrey T. Gibney, MD Associate Professor Co-leader, Melanoma Disease Group Lombardi Comprehensive Cancer Center
More informationDefinitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)
CROHN S DISEASE Definitions Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) Recurrence: The reappearance of lesions after surgical resection Endoscopic remission:
More informationCASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease
CASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease Maria Isabel Fiel, M.D. The Mount Sinai Medical Center New York, New York Case A 57 yo man, 7 months
More informationDiarrhoea for the Acute Physician
Diarrhoea for the Acute Physician STEPHEN INNS GASTROENTEROLOGIST AND PHYSICIAN HUTT VALLEY DHB August 2013 Outline Case History 1 Initial assessment of acute diarrhoea Management of fulminant UC Management
More informationGastrointestinal Toxicities of Checkpoint Blockade
Gastrointestinal Toxicities of Checkpoint Blockade Michael Dougan, MD, PhD Director of the Immunotherapy Mucosal Toxici:es Program Massachuse;s General Hospital 28 June 2018 Disclosures Novar:s Pharmaceu:cs
More information-2002: Rectal blood loss, UC? (no definite diagnosis) rectal mesalazine. -June 2008: Recurrence of rectal blood loss and urgency
SD, male 40 yrs. old. (680718M467.) -2002: Rectal blood loss, UC? (no definite diagnosis) rectal mesalazine -June 2008: Recurrence of rectal blood loss and urgency Total colonoscopy: ulcerative rectitis,
More informationDisclosure. Learning Objectives 4/25/2014. I have no disclosures
Alka Goyal MD Division of Pediatric Gastroenterology Hepatology and Nutrition Children s Hospital of Pittsburgh of UPMC Disclosure I have no disclosures Learning Objectives Diagnosis of Eosinophilic Esophagitis
More informationWhat do we need for diagnosis of IBD
What do we need for diagnosis of IBD Kaichun Wu Dept. of Gastroenterology, Xijing Hospital Fourth Military Medical University Xi an an,, China In China UC 11.6/10 5,CD 1.4/10 5 Major cause of chronic diarrhea
More informationHealthcare Professional. Frequently Asked. Questions. Brochure
YERVOY (ipilimumab) Healthcare Professional Frequently Asked Questions Brochure YERVOY is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. 1 This medicinal product
More informationPouchitis and Cuffitis A bloody mess. Sze-Lin Peng Colorectal Surgeon Counties Manukau District Health Board
Pouchitis and Cuffitis A bloody mess Sze-Lin Peng Colorectal Surgeon Counties Manukau District Health Board Ileal-pouch anal anastomosis https://www.pennmedicine.org/for-health-care-professionals/for-physicians/physician-education-and-resources/clinicalbriefings/2018/february/total-proctocolectomy-with-jpouch-reconstruction-for-ulcerative-colitis
More information6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)
Melanoma John A Thompson MD July 17, 2016 Featuring: Updates on immune checkpoint therapies Molecularly targeted therapies FDA approval for talimogene laherparepvec (T- VEC) 1 Mechanism of ac-on of Ipilimumab
More informationApproach to the Patient with Liver Disease
Approach to the Patient with Liver Disease Diagnosis of liver disease Careful history taking Physical examination Laboratory tests Radiologic examination and imaging studies Liver biopsy Liver diseases
More informationSerologic Markers CONVENTIONAL ANTIBODIES ANTIBODIES UNCONVENTIONAL. AIH Type I
Autoimmune Hepatitis By Thomas Frazier Objective What we need to know about AIH Diagnosis Treatment Difficulties in both Liver transplantation concerns AASLD Guidelines: Hepatology. 2010 Jun;51(6):2193-213.
More informationIBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition
IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel
More informationImplementation of disease and safety predictors during disease management in UC
Implementation of disease and safety predictors during disease management in UC DR ARIELLA SHITRIT DIGESTIVE DISEASES INSTITUTE SHAARE ZEDEK MEDICAL CENTER JERUSALEM Case presentation A 52 year old male
More informationAn Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University
More informationTitle: Author: Journal:
IMPORTANT COPYRIGHT NOTICE: This electronic article is provided to you by courtesy of Ferring Pharmaceuticals. The document is provided for personal usage only. Further reproduction and/or distribution
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationOptimal management of auto-immune
collaborations des équipes impliquées dans l' explorati en charge des ef ets indésirables des immunothérapies INSCRIPTIONS BLIC : cialistes d organe, Chercheur s, ovigilants ns l es toxicités es anti-cancéreuses.
More informationAdverse events in immunotherapy. Ramy Ibrahim, MD Clinical VP Immuno-Oncology Global Medicine Development AstraZeneca
Adverse events in immunotherapy Ramy Ibrahim, MD Clinical VP Immuno-Oncology Global Medicine Development AstraZeneca Unique features of immune-related Adverse Events iraes Non-specific Inflammation of
More informationManagement of common chemotherapy related side effects. Dr Lee-Ann Jones
Management of common chemotherapy related side effects Dr Lee-Ann Jones Deciphering oncology terms treatment intent Chemotherapy terms / intents Adjuvant chemotherapy - Chemotherapy given to destroy residual/
More informationAAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease
AAIM: GI Workshop Follow Up to Case Studies Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease Daniel Zimmerman, MD VP and Medical Director, RGA Global October 2015 Non-alcoholic Fatty
More informationImmunotherapies. Supporting health professionals to safely care for patients receiving immunotherapy in the cancer setting.
Immunotherapies Supporting health professionals to safely care for patients receiving immunotherapy in the cancer setting. INDEX Select a topic below for more information Principles of immunotherapy Classes
More informationManaging Adverse Events Associated with Immuno-oncologic Agents
Managing Adverse Events Associated with Immuno-oncologic Agents Jennifer Diehl RN, BSN, OCN Cutaneous Oncology Program Moffitt Cancer Center Tampa, FL September 10, 2015 12-1 p.m. EST ICLIO ecourse 05
More informationINFLAMMATORY BOWEL DISEASE
1. Medical Condition INFLAMMATORY BOWEL DISEASE (IBD) specifically includes Crohn s disease (CD) and ulcerative colitis (UC) but also includes IBD unclassified (IBDu), seen in about 10% of cases. These
More informationENDOCRINE ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT IMMUNOTHERAPY
ENDOCRINE ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT IMMUNOTHERAPY Lauren Clarine DO, Renil Rodriguez Martinez MD, Matthew Levine MD, Amy Chang MD, and Megan McGarvey MD May 6, 2017 Immune checkpoint inhibitors
More informationPositioning New Therapies
Positioning New Therapies Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker Disclosure Stephen Hanauer, MD has disclosed
More informationKids Like to Break the Rules: Gastrointestinal Pathology in Children
Kids Like to Break the Rules: Gastrointestinal Pathology in Children Jeffrey Goldsmith MD Director of Surgical Pathology, Beth Israel Deaconess Medical Center; Consultant in Gastrointestinal Pathology,
More information